
Contents

Part I Basic Area

1	Molecular Mechanisms of Estrogen Action in Target Tissues <i>B. Nicolás Díaz Chico, Domingo Navarro Bosch, Juan C. Díaz Chico, Eduardo Escrich Escriche</i>	3
1.1	Introduction	3
1.2	General Aspects	4
1.2.1	The Discovery of Hormone Receptors for Steroid Hormones	4
1.2.2	Nuclear Hormone Receptors?	5
1.3	Structure of Estrogen Receptors	7
1.3.1	Primary Structure of Estrogen Receptors	7
1.3.2	Activity Domains in the Molecules of Estrogen Receptors ...	8
1.3.3	Genetic Encoding of Estrogen Receptors	8
1.3.4	Native Receptor	10
1.3.5	Estrogen Transforms the Native Receptor	11
1.3.6	Domain of Nuclear Location	11
1.4	Hormone–Receptor Interaction	12
1.4.1	Ligand Binding Domain	12
1.4.2	Structure of Receptor and Hormonal Antagonism	14
1.4.3	Receptor Folding in Separate Domains	16
1.4.4	Dimerization Domains	17
1.5	Receptor–Genome Interaction	18
1.5.1	Specific DNA Sequences for the Hormone Response	18
1.5.2	DNA-Binding Domain	19
1.5.3	Recognition of Hormone Response Element	21
1.5.4	Role of Receptor–Hormone Response Element Complex ...	22
1.6	Hormonal Regulation of Gene Transcription	23
1.6.1	Domains of Transcription Activation (Transactivators)	24
1.6.2	Intermediary Transcription Cofactors	25
1.6.3	Interaction of Receptor with Transcription Cofactors	27
1.6.4	Coactivators in Cellular and Gene Promoter Context	27
1.6.5	Concept of SERM from Point of View of Coactivator	29

1.6.6	Structure of Chromatin and Hormone Response	29
1.6.7	Specificity of Gene Transcription Induced by Hormones	31
1.6.8	Multiple Regulation of Gene Expression	31
1.6.9	Nuclear Hormone Receptors and Endocrine Disruptors	32
1.7	Regulation of Intensity of Hormone Response	33
1.7.1	Membrane Receptors for Steroid Hormones	33
1.7.2	Regulation of Concentration of Receptors per Cell	34
1.7.3	Receptor Destiny After Activation	35
1.8	Cross-Talk Signaling	35
1.9	Silencing of Genes for Nuclear Hormone Receptors	37
1.10	Summary	39
	References	41
2	Clinical Pharmacology of Selective Estrogen Receptor Modulators (SERMs)	
	<i>Fernando Marín, M^a Carmen Barbancho</i>	49
2.1	Introduction	49
2.2	Classification	50
2.3	Pharmacological Characteristics of SERMs	52
2.3.1	Triphenylethylenes	52
2.3.2	Benzothiophenes	55
2.3.3	Naphthalenes	57
2.3.4	Indoles	58
2.3.5	Benzopyrans	60
2.4	Conclusions	62
	References	65
3	Action of Selective Estrogen Receptor Modulators (SERMs) Through the Classical Mechanism of Estrogen Action	
	<i>Fernando Marín, M^a Carmen Barbancho</i>	71
3.1	Introduction	71
3.2	Estrogen Receptor Subtypes	72
3.3	Conformation of Ligand-ER Complex	73
3.4	Coregulator Protein Cell Content and Coactivators/Corepressors Ratio	73
3.5	Transrepression: Regulation of Gene Expression by an ERE-Independent Mechanism	75
	References	76

4	Cellular and Molecular Basis for Acute Nongenomically Mediated Actions of SERMs <i>Mario Díaz, Jorge Marrero-Alonso, Benito García Marrero, Raquel Marín, Tomás Gomez, Rafael Alonso</i>	79
4.1	Introduction	79
4.2	Cellular and Molecular Targets for Rapid Actions	79
4.2.1	Interaction with Ion Channels	79
4.2.2	Multidrug Resistance and P-glycoprotein	86
4.2.3	Signalling Transducers	87
4.2.4	Lipids, Membrane Lipids, and Fluidity	92
4.2.5	Specific Antiestrogen-Binding Sites (AEBS)	94
4.3	Final Considerations	95
	References	96
5	The Hypothalamus–Pituitary–Ovarian Axis as a Model System for the Study of... SERM Effects: An Overview of Experimental and Clinical Studies <i>R. Alonso, F. Marín, M. González, P. Guelmes, C. Bellido, G. Hernández, R. Marín, M. Díaz, J.E. Sánchez-Criado</i>	103
5.1	Introduction	103
5.2	Hypothalamus-Pituitary-Ovarian Axis of Mammals	104
5.2.1	General Aspects	104
5.2.2	Functional Organization	105
5.2.3	Estrogen Feedback Regulation of Hypothalamus-Pituitary Axis	106
5.2.4	Overview of Hypothalamic-Pituitary Function at Time of Gonadotropin Surge	112
5.3	Effects of SERMs on Hypothalamus-Pituitary-Ovarian Axis	114
5.3.1	Experimental Studies in the Rat	115
5.3.2	Lessons in SERM Behavior from Effects of Tamoxifen on Rat Pituitary Function	119
5.3.3	Clinical Studies	122
5.4	Summary and Conclusions	126
	References	127
6	Pure Antiestrogens <i>Carlos Hermenegildo</i>	141
6.1	Introduction	141
6.1.1	Type I	141
6.1.2	Type II	141
6.2	Chemical Structure and Classification	142

6.3	Mechanism of Action	143
6.4	Effects of Pure Antiestrogens	146
6.4.1	In Vitro Studies	146
6.4.2	Experiments in Animals	147
6.4.3	Clinical Studies	150
6.5	Clinical Utility	152
	References	153

Part II Clinical Area

7	Physiological Regulation of Bone Metabolism and Estrogen Agonism	
	<i>Miguel Angel García-Pérez</i>	161
7.1	Normal Bone Remodeling	162
7.2	Executive Cells: Osteoblasts and Osteoclasts	163
7.3	Role of Proinflammatory Cytokines in Bone Resorption	166
7.4	The RANKL/RANK/OPG System	167
7.5	Bone Remodeling After Estrogen Deficiency	171
7.6	Effects of Estrogen and Agonist of Estrogen Receptor on Bone Cells	174
7.7	Conclusions	177
	References	177
8	The Role of SERMs in the Treatment of Osteoporosis	
	<i>Adolfo Díez-Pérez, José Luis Dueñas-Díez</i>	187
8.1	Introduction	187
8.2	Experimental Results	188
8.2.1	Tamoxifen	188
8.2.2	Raloxifene	188
8.3	Other SERMs	189
8.4	Clinical Effects of SERMs	190
8.4.1	Tamoxifen	190
8.4.2	Raloxifene	192
8.5	Bone Quality and Its Relevance	195
8.6	Future SERMs	199
	References	199
9	Cardiovascular Disease and SERMs	
	<i>Antonio Cano</i>	207
9.1	The Focal Phenotype of CVD	208
9.1.1	The Crucial Role of the Endothelium	210
9.2	Estrogen Agonism and CVD	212

9.2.1	Lipids	212
9.2.2	Vascular Wall	213
9.3	SERMs as an Alternative to Estrogens in CVD	214
9.4	Actions of SERMs	216
9.4.1	Arterial Disease	216
9.4.2	VTED	226
9.5	Conclusion and Outlook for the Future	227
	References	228
10	SERMs and the Breast	
	<i>Joaquim Calaf i Alsina, Antonio Cano Sanchez</i>	239
10.1	Introduction	239
10.2	Biology of Breast Development and its Endocrine Regulation	240
10.3	Framework of Breast Cancer Research	241
10.4	Relationship Between Estrogens and Breast Cancer	243
10.4.1	Endogenous Estrogens	243
10.4.2	Exogenous Estrogens	244
10.5	Pharmacological Blockade of Estrogen Receptors:	
	The Concept of Chemoprophylaxis	247
10.5.1	Tamoxifen as Adjuvant Therapy	
	in Early ER(+) Breast Cancer	248
10.5.2	Tamoxifen in Primary Prevention of ER(+) Breast Cancer...	250
10.5.3	Drawbacks of Tamoxifen as a Preventive Agent	252
10.6	Raloxifene and Breast Cancer	255
10.6.1	Clinical Studies	255
10.6.2	Estrogen Receptor Status	258
10.6.3	Estrogen Circulating Levels and Raloxifene Protection	258
10.6.4	Bone Density and Effect of Raloxifene on the Breast	260
10.6.5	Other Conditions Related to Raloxifene Protection	262
10.6.6	Raloxifen as a Breast Cancer Preventive Agent	264
10.7	New Perspectives	265
	References	266
11	Endometrial Effects of SERMs	
	<i>Santiago Palacios</i>	271
11.1	Introduction	271
11.2	Mechanism of Action in the Endometrium	271
11.2.1	Tamoxifen	272
11.2.2	Raloxifene	274
11.3	Tamoxifen and Endometrium: Clinical Consideration	275
11.3.1	Ultrasonographic Findings	275

11.3.2	Hystological Findings	275
11.3.3	Tamoxifen and Risk of Endometrial Cancer	277
11.4	Raloxifene	279
11.4.1	Data Obtained from Biopsy	279
11.4.2	Ultrasonographic Data and Symptomatology	280
11.5	Others SERMs	283
11.5.1	Arzoxifene	283
11.5.2	Bazedoxifene Acetate	283
11.5.3	Lasofoxifene	284
11.5.4	Ospemifene	284
11.6	Conclusions	285
	References	285
12	Benign Gynecological Diseases and SERMs	
	<i>Stefano Palomba, Fulvio Zullo</i>	291
12.1	Introduction	291
12.2	Uterine Leiomyomas	291
12.2.1	Treatments of Uterine Leiomyomas	292
12.2.2	SERMs and Uterine Leiomyomas	294
12.3	Endometriosis	302
12.3.1	Treatments of Endometriosis	303
12.3.2	SERMs and Endometriosis	304
12.4	Conclusions	305
	References	306
13	Other Clinical Effects of SERMs	
	<i>P. Ación, F. Quereda, M.I. Ación</i>	313
13.1	Urogenital Tract	314
13.1.1	Vaginal Trophism and Dyspareunia	314
13.1.2	Pelvic Floor Function and Urinary Disorders	315
13.2	Central nervous system	318
13.2.1	Hot Flashes and Beta Endorphins	320
13.2.2	Mood, Sleep, Waking Episodes	321
13.2.3	Cognitive Function, Alzheimer's Disease (AD)	321
13.2.4	Libido, Sexual Function	323
13.3	Gallbladder and Hepatobiliar System	324
13.4	Desmoids and Mesenteric Fibromatosis	325
13.5	Endocrine Functions	325
13.5.1	Insulin Sensitivity and Diabetes	325
13.5.2	Thyroid Function	325
13.6	Eye, Cataracts	326

13.7 Other Effects	328
13.7.1 Arthritis.....	328
13.7.2 Hemorheological Effects	328
13.7.3 Quality of Life (QoL)	328
References	329
14 The Role of SERMs in the Management of Postmenopausal Women	
<i>Joaquim Calaf i Alsina</i>	333
14.1 Introduction	333
14.2 Identifying Troubles and Threats.....	334
14.2.1 Cardiovascular Risk	334
14.2.2 Menopausal Syndrome	335
14.2.3 Osteoporosis	336
14.2.4 Breast Cancer	337
14.3 Intervention Tools	338
14.3.1 Lifestyle Optimization	338
14.3.2 Hormone Therapy	338
14.3.3 Cardioprotective Treatments	339
14.3.4 Bone Resorption Inhibitors	339
14.3.5 Breast Cancer Risk.....	340
14.4 Addressing Health Expectancy Improvement	340
14.4.1 Poly Approach and Multitasking.....	340
14.4.2 Pharmacological Poly Approach	341
14.4.3 Multitasking Drugs	342
14.5 Dynamic Decision-Making Diagram	344
References	346
Subject Index	351

Selective Estrogen Receptor Modulators

A New Brand of Multitarget Drugs

Cano, A.; Calaf i Alsina, J.; Duenas-Diez, J.L. (Eds.)

2006, XVII, 357 p., Hardcover

ISBN: 978-3-540-24227-7